PURPOSE:

This paper provides a copy of the Board’s decisions that were taken electronically after the end of the Twenty-Second Board Meeting until the start of the Twenty-Third Board Meeting.
January 2011 Phase 2 Funding Decision

Confirmed 31 January 2011

Decision Point GF/B22/EDP/1

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)\(^1\).

2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

Table 1: January 2011 Phase 2 Funding Recommendations

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DRC, HIV, Round 7</td>
<td>ZAR-708-G06-H</td>
<td>US$ 48,727,979</td>
<td>US$ 31,845,797</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>2</td>
<td>Ethiopia, HIV, Round 7</td>
<td>ETH-708-G08-H</td>
<td>US$ 7,056,352</td>
<td>US$ 1,310,862</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>3</td>
<td>Guinea Bissau, HIV, Round 7</td>
<td>GNB-708-G05-H</td>
<td>Euros 23,212,615</td>
<td>US$ 19,360,883 = Euros 14,951,248*</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>4</td>
<td>Honduras, HIV, RCC</td>
<td>HND-102-G04-H-00</td>
<td>US$ 19,142,757</td>
<td>US$ 18,509,581</td>
<td>Go</td>
</tr>
</tbody>
</table>

\(^1\) Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.
<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Madagascar, Malaria, Round 7</td>
<td>MDG -708-G10-M</td>
<td>US$ 19,421,933</td>
<td>US$16,143,121</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>6</td>
<td>Malawi, TB Round 7</td>
<td>MLW-708-G06-T</td>
<td>US$ 7,390,126</td>
<td>US$ 3,421,166</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>7</td>
<td>Mongolia, TB, RCC</td>
<td>MON-102-G01-T-00</td>
<td>US$ 4,411,110</td>
<td>US$ 4,274,480</td>
<td>Go</td>
</tr>
<tr>
<td>8</td>
<td>Mongolia, HIV, RCC</td>
<td>MON-202-G02-H-00</td>
<td>US$ 2,710,890</td>
<td>US$ 2,611,880</td>
<td>Go</td>
</tr>
<tr>
<td>9</td>
<td>Rwanda, Malaria, RCC</td>
<td>RWN-304-G03-M</td>
<td>US$ 25,746,783</td>
<td>US$ 23,416,456</td>
<td>Go</td>
</tr>
<tr>
<td>10</td>
<td>Sao Tome &amp; Principe, Malaria, Round 7</td>
<td>STP-708-G03-M</td>
<td>US$ 4,107,976</td>
<td>US$ 3,692,053</td>
<td>Go</td>
</tr>
<tr>
<td>11</td>
<td>Tanzania, Malaria, Round 7</td>
<td>TNZ-708-G10-M</td>
<td>US$ 26,995,075</td>
<td>US$ 15,919,263</td>
<td>Conditional Go</td>
</tr>
</tbody>
</table>

(*) The Guinea Bissau Round 7 HIV proposal was approved in US$; however, the CCM has requested Phase 2 funding in Euro currency. To give the Board the most up-to-date picture of what the USD/EUR equivalent is at the time of the Phase 2 submission, the recommended incremental funding amount has been computed in Euros using the rate of exchange that is published at [www.oanda.com](http://www.oanda.com) on 12 January 2011 (US$ 1= Euro 0.77224).

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Commitment of additional funding for Prevention of Mother to Child Transmission (PMTCT) activities during the Phase 2 term of the Round 6 South Africa HIV grant (SAF-607-G06-H)

Confirmed 31 January 2011

Decision Point GF/B22/EDP/02:

The Board approves additional funding up to US$ 13,055,416 for the Phase 2 period of the Round 6 South Africa HIV grant (SAF-607-G06-H) to improve the quality and scale of PMTCT activities, subject to Technical Review Panel (TRP) clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US$ 37,951,822 which includes an additional sum of US$ 13,055,416 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Extension of time required to fulfill a ‘condition’ in the Phase 2 term of the Round 6 Kenya Tuberculosis grant (KEN-607-G08-T)

Confirmed 31 January 2011

Decision Point GF/B22/EDP/03:

The Board:

1. Refers to condition number 5 in its decision approving as a ‘Conditional Go’ the Phase 2 of the Kenya Round 6 TB grant (KEN-607-G08-T) (“Condition 5”) which states that: “Not later than 30 September 2010, the Principal Recipient must finalize and submit to the Global Fund the reports for the audits of the Financial Management Agent and the Procurement Consortium,” and

2. Decides to extend the deadline in Condition 5 from 30 September 2010 to 31 March 2011.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Extension of time required to fulfill two ‘conditions’ in the Phase 2 term of the
Round 6 Zanzibar HIV grant (ZAN-607-G05-H)

Confirmed 31 January 2011

Decision Point GF/B22/EDP/04:

The Board decides:

1. to revise Conditions 2 and 3 to its Phase 2 approval for the Round 6 Zanzibar HIV (ZAN-607-G05-H) grant as follows:

   Condition 2 shall be revised to: “Within 6 months of the signing of the Phase 2 extension the Secretariat will review a repeat LFA On Site Data Verification (OSDV) to determine whether 1) this reconfirms the number of people on ARV treatment at that time, 2) actions recommended from the first OSDV have been implemented and 3) there are appropriate systems in place to ensure quality data.”

   Condition 3 shall be revised to: “Within 6 months of the signing of the Phase 2 extension the PR shall have completed working with technical agencies on an independent performance review of the Program and provide this independent performance review to the Global Fund. Continuation of funding for years 4 and 5 under the Program is subject to a determination by the Secretariat that the independent performance review demonstrates an efficient use of resources under the Program.”

2. that if Condition 3, as revised, is not fulfilled within the timescale set then the Secretariat is to proceed to terminate the grant.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Extend Phase 1 period of the Round 7 Tanzania Malaria grant (TNZ-708-G10-M)

Confirmed 31 January 2011

Decision Point GF/B22/EDP/05:

The Board acknowledges that additional time is required for the Phase 1 implementation period for the Tanzania Round 7 Malaria grant (TNZ-708-G10-M) in order to allow the grant to be consolidated with the Round 9 grant into a Single Stream of Funding and to ensure that AMFm activities are not interrupted during this time. The Board therefore approves the extension of the Phase 1 period for the Round 7 malaria grant (TNZ-708-G10-M) by an additional 3 months until 31 March 2011 without committing additional funding for the Phase 1 period.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
February 2011 Phase 2 Funding Decision

Confirmed 12 February 2011

Decision Point GF/B22/EDP/06:

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)\(^1\).

2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

Table 1: February 2011 Phase 2 Funding Recommendations

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Angola, Malaria, Round 7</td>
<td>AGO-708-G04-M</td>
<td>US$ 31,599,523</td>
<td>US$ 24,832,565</td>
<td>Conditional Go</td>
</tr>
<tr>
<td>2</td>
<td>Chad, Malaria, Round 7</td>
<td>TCD-708-G03-M</td>
<td>US$ 16,180,673</td>
<td>US$ 11,780,718</td>
<td>Go</td>
</tr>
<tr>
<td>3</td>
<td>Mozambique, TB, Round 7</td>
<td>MOZ-708-G07-T</td>
<td>US$ 8,129,484</td>
<td>US$ 7,643,253</td>
<td>Conditional Go</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US$ 44,256,536</td>
<td></td>
</tr>
</tbody>
</table>

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.

\(^1\) Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.
Board Approval of Additional Funding for the Round 7 Afghanistan HIV Grant (AFG-708-G04-H)

Confirmed 12 February 2011

Decision Point GF/B22/EDP/07:

The Board approves additional incremental funding up to US$ 30,000 for the Phase 2 period of the Round 7 Afghanistan HIV grant (AFG-708-G04-H) with conditions stipulated in its B21/EDP/27 decision of 19 November 2010. The Board approves the revised Phase 2 incremental amount up to US$ 513,579.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Funding discontinuation for the Round 6 Mauritania Malaria and TB grants

Confirmed 12 February 2011

Decision Point GF/B22/EDP/08:

The Board declines approval of additional funding for the Phase 2 period for the Round 6 Mauritania Malaria (MRT-607-G04-M) and TB (MRT-607-G05-T) grants.

Table 1: Funding discontinuation for Mauritania Round 6 Malaria and TB grants

<table>
<thead>
<tr>
<th>Country, Disease, Round</th>
<th>Grant Number</th>
<th>CCM Requested Amount (in US$ or Euros)</th>
<th>Recommended Funding Amount (Incremental in US$ or Euros)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Mauritania, Malaria, Round 6</td>
<td>MRT-607-G04-M</td>
<td>US$ 5,581,249</td>
<td>No additional funding</td>
</tr>
<tr>
<td>2. Mauritania, TB, Round 6</td>
<td>MRT-607-G05-T</td>
<td>US$ 4,215,422</td>
<td>No additional funding</td>
</tr>
</tbody>
</table>

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
**Extension to the grant signing deadline for Round 9 “Category 2B” proposals**

**Confirmed 15 February 2011**

**Decision Point GF/B22/EDP/09:**

The Board extends the deadline for the signing of grant documentation for the proposals listed in Table 1 for three months to 20 May 2011.

**Table 1: Extension of grant signing deadline for four grants in three countries**

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant information</th>
<th>Deadline for signature</th>
</tr>
</thead>
</table>
| 1  | Central African Republic, TB, Round 9 | Principal Recipient: Ministry of Public Health, Population and the fight against HIV/AIDS  
Total approved amount: Euros 20,972,227 over five years  
Phase 1 approved upper ceiling: Euros 8,961,795 | 20 May 2011 |
| 2  | Nigeria, TB, MDR-TB Component, Round 9 | Principal Recipient: IHVN  
Total amount: US$ 113,332,101 over five years  
Phase 1 (total): US$ 31,515,160  
Phase 1 (MDR TB component): US$ 9,002,945 | 20 May 2011 |
| 3  | Democratic Republic of Congo, Round 9 TB/HSS (2 grants) | Principal Recipients: i) Ministry of Health and ii) CARITAS  
Total amount (over 5 years): US$ 275,383,647  
Phase 1: US$ 100,261,325 | 20 May 2011 |

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Amendment of By-Laws and Board Operating Procedures: Appointment of Executive Director

Confirmed 3 March 2011

Decision Point GF/B22/EDP/10:

The Board approves to change:

1) Article 8. Secretariat, paragraph 8.1 of the By-Laws to read as follows:

8.1 Composition

The Secretariat is responsible for managing the day-to-day operations of the Foundation.

The Secretariat is headed by an Executive Director, who is selected by the Foundation Board based on merit, in a non-political, open and competitive manner. The Executive Director acts as the chief executive officer of the Foundation and serves for a term of four years, renewable for not more than one additional term of three years.

The Executive Director is responsible to the Foundation Board for the day-to-day management of the Foundation, and for specific duties and responsibilities assigned to him or her by the Foundation Board.

Secretariat staff are selected by the Executive Director, under policies and procedures approved by the Foundation Board.

2) Section D. ROLES AND RESPONSIBILITIES, paragraph 17 of the Board Operating Procedures to read as follows:

17. Executive Director

17.1 The Executive Director shall attend all Board Meetings, and shall be responsible for the preparation and distribution of all materials required for the meeting, and for such other duties and responsibilities as may be assigned by the Board or the Chair. The Executive Director shall be appointed by the Board for a term of four years, renewable for not more than one additional term of three years.

3) Section G. PROCEDURES FOR APPOINTMENT AND ASSESSMENT OF THE EXECUTIVE DIRECTOR, paragraph 26 of the Board Operating Procedures to read as follows:
26. Appointment of the Executive Director

26.1 No later than six months prior to the end of the term of the incumbent Executive Director, the Board shall, in accordance with Article 8.1 of the Bylaws and this Section of the Board Operating Procedures, decide on a procedure for the appointment of the next Executive Director.

26.2 At this time, the Board shall normally launch a competitive recruitment process, publicly inviting applications for the position of Executive Director. Where the incumbent Executive Director has not served more than one term of office, the Board may invite him or her to re-apply, together with other candidates, for such position and publicly announce such invitation. Where appropriate the Board may launch such a recruitment process without inviting the Executive Director to re-apply for the post or, based on a satisfactory performance appraisal and if the incumbent Executive Director has not served more than one term, extend the appointment of the Executive Director for a further term of three years without the normal recruitment process.

26.3 If When the Board decides to launch a recruitment process, it shall be assisted by an ad hoc Nomination Committee. At least six months prior to the end of the term of the incumbent Executive Director, or at any other time decided by the Board, the Chair of the Board shall, notwithstanding the otherwise applicable procedures under these Board Operating Procedures and the Committee Rules and Procedures, recommend for Board approval the terms of reference of the Nomination Committee and nominate for Board approval a Chair and the membership of that Committee. Membership in the Nomination Committee shall not count towards the two committee limit referenced in Section 23 of these Board Operating Procedures.

26.4 The Chair of the Board may also recommend for Board approval updated terms of reference of the Executive Director and the criteria for his or her selection. Following approval of the membership of the Nomination Committee, the recruitment process is launched.

26.5 The Nomination Committee shall interview and rank candidates, and present the highest ranking candidates to the Board, which shall then select a candidate, consistent with the terms of office of the Executive Director that are stated in Section 17 of these Board Operating Procedures.

26.6 The mandate of the Nomination Committee shall expire upon the appointment of the Executive Director.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Exceptional Extension to the Round 10 Submission Deadline

Confirmed 14 March 2011

Decision Point GF/B22/EDP/11:

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)[1].

2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

Table 1: March 2011 Phase 2 Funding Recommendations

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)*</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cambodia CAM-708-G12-T</td>
<td>US$ 12,369,715</td>
<td>US$ 11,184,266</td>
<td>Conditional Go</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Kyrgyzstan KGZ-708-G05-H</td>
<td>US$ 14,515,736</td>
<td>US$ 12,260,383</td>
<td>Go</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Nicaragua NIC-708-G04-M</td>
<td>US$ 0</td>
<td>US$ 2,289,392</td>
<td>Go</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Sudan SUD-708-G10-M</td>
<td>US$ 50,312,306</td>
<td>US$ 40,562,305</td>
<td>Go</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Timor-Leste TMP-709-G05-M</td>
<td>US$ 3,232,042</td>
<td>US$ 2,751,450</td>
<td>Go</td>
<td></td>
</tr>
</tbody>
</table>

NOTES: (*) These figures were submitted in the CCM request. Discrepancies with the CCM request figure in the GSC are due to the further adjustments made by the Global Fund Secretariat at the time of the Phase 2 review.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.

[1] Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.
Round 10 Independent Appeals Panel Recommendation

Confirmed 25 March 2011

Decision Point GF/B22/EDP/12:

1. The Board approves funding for the Round 10 Ethiopia Tuberculosis proposal for the Phase 1 Period of up to USD 21,107,334, as a ‘Category 2’ proposal recommended by the Independent Appeals Panel, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount and subject to satisfactory completion by the applicant of the requirements set out in paragraph 2 below:

2. The applicant shall:

   a) Provide an initial detailed written response to the clarifications and adjustments requested by the Independent Appeals Panel not later than six weeks after the receipt of the notification in writing by the Secretariat to the applicant of this Board decision; and

   b) Complete any further clarifications or adjustments, as required by the Chair or Vice-Chair of the Technical Review Panel, not later than three months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarifications or adjustments.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Membership of the Ethics Committee

Confirmed 1 April 2011

Decision Point GF/B22/EDP/13:

The Board approves the appointment of the Latin America and Caribbean Constituency as a member of the Ethics Committee until the adjournment of the Twenty-Third Board Meeting.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
April 2011 Phase 2 Funding Decision

Confirmed 12 April 2011

Decision Point GF/B22/EDP/14:

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)[1].

2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

Table 1: April 2011 Phase 2 Funding Recommendations

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)*</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Burundi, Malaria, RCC</td>
<td>BRN-202-G05-M-00</td>
<td>US$ $13,917,492</td>
<td>US$ 11,259,150</td>
<td>Go</td>
</tr>
<tr>
<td>2</td>
<td>Ethiopia, HIV, Round 7</td>
<td>ETH-708-G07-H</td>
<td>US$ 13,739,850.50</td>
<td>US$ 13,739,820</td>
<td>Go</td>
</tr>
<tr>
<td>3</td>
<td>Guyana, Malaria, Round 7</td>
<td>GYA-708-G04-M</td>
<td>US$ 880,247</td>
<td>US$ 958,091**</td>
<td>Go</td>
</tr>
<tr>
<td>4</td>
<td>Suriname, Malaria, Round 7</td>
<td>SUR-708-G04-M</td>
<td>US$ 1,572,300</td>
<td>US$ 1,548,737</td>
<td>Go</td>
</tr>
<tr>
<td>5</td>
<td>Swaziland, HIV, Round 7</td>
<td>SWZ-708-G05-H</td>
<td>US$ 47,969 374</td>
<td>US$ 36,628,401</td>
<td>Conditional Go</td>
</tr>
</tbody>
</table>

[1] Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.
NOTES:
(*) These figures were submitted in the CCM request. Discrepancies with the CCM request figure in the GSC are due to the further adjustments made by the Global Fund Secretariat at the time of the Phase 2 review.

(**) At the time of the request, the CCM mistakenly excluded costs for antimalarials. Additionally, the costs for the Deputy Director post, a KAP survey and an independent review were later added. Thus, Secretariat’s recommended amount is larger than CCM’s.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Additional funding to the Round 7 West Bank and Gaza Strip HIV Proposal

Confirmed 12 April 2011

Decision Point GF/B22/EDP/15:

The Board:

1. Approves additional funding for the Phase 2 period of the Round 7 West Bank and Gaza Strip (PSE-708-G01-H) grant as a ‘Conditional Go’ in the amount of up to US$ 4,985,587, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).

2. The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
Extension of Grant Ending Date For the Round 8 Ghana Malaria Grant (GHN-809-G08-M)

Confirmed 29 April 2011

Decision Point GF/B22/EDP/16:

The Board extends the Phase 1 Ending Date of the Ghana Malaria Grant GHN-809-G08-M from 31 December 2011 to 31 December 2012, and subject to approval of Phase 2 of this Grant, authorises the extension of the Phase 2 Ending Date from 31 December 2014 to 31 December 2015.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.
May 2011 Phase 2 Funding Approval

Confirmed 10 May 2011

Decision Point GF/B22/EDP/17:

The Board:

1. Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)[1].

2. Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.

Table 1: May 2011 Phase 2 Funding Recommendations

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number(s)</th>
<th>CCM Requested Amount (Incremental in US$ or Euros)*</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
<th>Recommendation Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Kenya, HIV, Round 7</td>
<td>KEN-708-G10-H</td>
<td>US$ 18,884,940</td>
<td>US$ 12,518,575</td>
<td>Go</td>
</tr>
<tr>
<td>2</td>
<td>Tanzania Malaria, Round 7</td>
<td>TNZ-102-G01-M-00</td>
<td>US$ 7,688,058</td>
<td>US$ 6,366,365</td>
<td>Conditional Go</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US$ 18,884,840</td>
</tr>
</tbody>
</table>

NOTES: (*) These figures were submitted in the CCM request. Discrepancies with the CCM request figure in the GSC are due to the further adjustments made by the Global Fund Secretariat at the time of the Phase 2 review.

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.

[1] Where the Board approves additional funding for a period greater than two years, the Secretariat is required to commit that additional funding is limited to two years. A third year of additional funding may subsequently be committed by the Secretariat, not earlier than eighteen months from the start of additional funding, conditional upon the availability of funding.
Additional funding for Continuity of Services to the Round 3 Yemen HIV grant (YEM-307-G05-H)

Confirmed 10 May 2011

Decision Point GF/B22/EDP/18:

The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1 [1].

Table 2: May 2011 Continuity of Services Funding Approval

<table>
<thead>
<tr>
<th>No</th>
<th>Country, Disease, Round</th>
<th>Grant Number</th>
<th>CCM Requested Amount (in US$ or Euros)</th>
<th>Approved Funding Amount (Incremental in US$ or Euros)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yemen, HIV, Round 3</td>
<td>YEM-307-G05-H</td>
<td>US$ 1,009,813</td>
<td>US$ 400,572</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US$ 400,572</td>
</tr>
</tbody>
</table>

This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.